We reviewed results of immunotherapy in patients with demyelinating mo
tor neuropathy (DMN), and found that patients over 50 years of age at
onset responded poorly, and younger patients responded variably to int
ervention. We suggest that patients with DMN be given a guarded progno
sis, particularly if >50 years of age at onset. (C) 1998 John Wiley &
Sons, Inc.